Deal of the Day — limited-time pharmacy picks!
Obparp 150mg Tablet

Obparp 150mg Tablet

Prescription requiredRx Required

Salt Composition: Olaparib

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

8 tablet in strip

About The Product

Ovarian Cancer, Breast Cancer

Obparp 150mg Tablet is a prescription based medicine with Olaparib (150mg) as an active ingredient. It is used in the treatment of breast cancer and ovarian cancer. It works by blocking the action of an enzyme known as PARP, that helps to fix damaged DNA.

As a result by stopping the action of PARP, Lupiparp prevents cancer cells from repairing themselves, which cause them to die off & slowing tumor growth. It should be taken in dose and duration as advice by the doctor. Don't take more than the recommended dose.

Uses

  • Breast cancer
  • Ovarian cancer

Side Effects

Obparp 150mg Tablet may cause some side effects that vary from one patient to another. Most side effects do not require any medical attention and disappear as your body adjusts to the medicine.

Common side effects include:

  • Nausea
  • Vomiting
  • Fatigue
  • Diarrhea
  • Loss of appetite
  • Anemia (low number of red blood cells)
  • Headache
  • Decreased blood cells (red cells, white cells, and platelets)
  • Taste change
  • Cough
  • Breathlessness
  • Indigestion
  • Abdominal pain

Contact your healthcare provider if you face any unusual or persistent side effects.

How To Use

  • Take Obparp 150mg in exact dose as prescribed by the doctor.
  • The typical dose of this capsule varies with age and overall health factor of the patient.
  • It can be taken with or without food but at a fixed time each day to get better results.
  • It should be swallowed as a whole with water without crushing, chewing, or opening the capsule.
  • Don't miss a dose or overdose the medicine. ​

How It Works

Obparp 150mg Tablet is a prescription based anticancer medicine with Olaparib (150mg) as an active ingredient. It works by blocking the action of an enzyme known as PARP, that helps to fix damaged DNA.

As a result by stopping the action of PARP, Lupiparp prevents cancer cells from repairing themselves, which cause them to die off & slowing tumor growth. Also it can decrease tumor growth in both as monotherapy or following chemotherapy.

Safety Advice

Alcohol
Avoid the consumption of alcohol while taking Obparp 150mg Tablet, as alcohol can decrease the effectiveness of the medicine as well as worsen the symptoms.
Pregnancy
Do not take Obparp 150mg Tablet without consulting the doctor in case of pregnancy, as it can be unsafe to take it during this period.
Breast Feeding
Breastfeeding women should discuss the potential risks and benefits of the Obparp 150mg Tablet with their healthcare provider before starting treatment.
Driving
Obparp 150mg Tablet may cause side effects such as dizziness or lack of concentration, which could affect your ability to drive. So it's better to avoid driving.
Kidney
Obparp 150mg Tablet is safe for use in kidney disease if prescribed by the doctor. No dosage adjustment is necessary for this Tablet.
Liver
Obparp 150mg Tablet is safe for use in liver disease if prescribed by the doctor. No dosage adjustment is necessary for this Tablet.Obparp 150mg Tablet is safe for use in liver disease if prescribed by the doctor. No dosage adjustment is necessary for this Tablet.

FAQs

Obparp 150mg Tablet is an anti-cancer medication that is prescribed for the treatment of breast cancer and ovarian cancer.

References

  • Robert, M., Frenel, J. S., Gourmelon, C., Patsouris, A., Augereau, P., & Campone, M. (2017). Olaparib for the treatment of breast cancer. Expert opinion on investigational drugs, 26(6), 751-759.
  • Robson, M., Im, S. A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., ... & Conte, P. (2017). Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine, 377(6), 523-533.
  • Griguolo, G., Dieci, M. V., Guarneri, V., & Conte, P. (2018). Olaparib for the treatment of breast cancer. Expert review of anticancer therapy, 18(6), 519-530.
  • Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., ... & Harter, P. (2019). Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England Journal of Medicine, 381(25), 2416-2428.
  • Bixel, K., & Hays, J. L. (2015). Olaparib in the management of ovarian cancer. Pharmacogenomics and personalized medicine, 127-135.
  • Moore, K., Colombo, N., Scambia, G., Kim, B. G., Oaknin, A., Friedlander, M., ... & DiSilvestro, P. (2018). Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine, 379(26), 2495-2505.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026